PROK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PR

Mkt Cap

$276.8M

Volume

1.51M

Next Earnings

November 9th

Loading chart

PR

PROKProKidney Corp. Class A Ordinary Shares

PROK

Pay with—

Available Balance0.00

PR

Mkt Cap

$277.9M

Volume

1.51M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026ProKidney announced that eight abstracts, including one oral presentation, will be presented at ASN's Kidney Week 2026 in Denver. The abstracts present translational research and a pooled Phase 2 analysis supporting rilparencel's multifactorial mechanism of action for treating chronic kidney disease with type 2 diabetes, demonstrating kidney function stabilization and a strong safety profile.GlobeNewswire Inc. · Oct 2, 2026

ProKidney Reports Full Year 2025 Financial Results and Business HighlightsProKidney reported full-year 2025 financial results with $270.0 million in cash and cash equivalents, supporting operations into mid-2027. The company achieved significant milestones including FDA alignment on an accelerated approval pathway for rilparencel using eGFR slope as a surrogate endpoint, positive Phase 2 REGEN-007 results, and strong enrollment momentum in the Phase 3 PROACT 1 study. The company expects to complete enrollment for the accelerated approval analysis by mid-2026 and deliver pivotal topline results in Q2 2027.GlobeNewswire Inc. · Mar 18, 2026

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025ProKidney presented Phase 2 trial results showing rilparencel potentially slows chronic kidney disease progression in diabetic patients, with statistically significant improvements in estimated glomerular filtration rate (eGFR) slope and no serious adverse events.GlobeNewswire Inc. · Nov 6, 2025

Play Likely Earnings Beat With 3 Top-Ranked StocksTop-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.Zacks Investment Research · Jun 21, 2024

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingWINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered direct offering are each expected to close on or about June 13, 2024, subject to customary closing conditions. The underwritten public offering is not contingent on the closing of the concurrent direct offering, and the concurrent direct offering is not contingent on the closing of the underwritten public offering.GlobeNewswire Inc. · Jun 12, 2024

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingWINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses. ProKidney expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company.GlobeNewswire Inc. · Jun 10, 2024

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational UpdatesWINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company’s renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical and operational updates. Management will host a live webcast today at 8:00 a.m. ET to discuss the data.GlobeNewswire Inc. · Jun 10, 2024

ProKidney Reports Business Updates and First Quarter 2024 Financial ResultsWINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the first quarter ended March 31, 2024.GlobeNewswire Inc. · May 10, 2024

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionShares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives. SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday. Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday. Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies. Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650. HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday. Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...Benzinga · Apr 15, 2024

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical OperationsDr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapiesGlobeNewswire Inc. · Mar 25, 2024

to start trading

PR

PROKProKidney Corp. Class A Ordinary Shares

PROK

Pay with—

Available Balance0.00

Your PositionYou don't own any PROK yet.

Related Tickers

Earnings